A Study of BL-B01D1+PD-1/PD-L1 Monoclonal Antibody in Patients With Advanced Biliary Tract Cancer

NCT ID: NCT06978114

Last Updated: 2025-07-02

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: PHASE2
• Total Enrollment: 46 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2025-06-10
• Study Completion Date: 2027-12-31

Brief Summary

This study is a clinical study to explore the efficacy and safety of BL-B01D1+PD-1/PD-L1 monoclonal antibody in patients with advanced biliary tract cancer.

Conditions

Advanced Biliary Tract Cancer

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

BL-B01D1+Pembrolizumab

Participants receive BL-B01D1+Pembrolizumab in the first cycle (3 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.

Group Type: EXPERIMENTAL

BL-B01D1

Intervention Type: DRUG

Administration by intravenous infusion for a cycle of 3 weeks.

Pembrolizumab

Intervention Type: DRUG

Administration by intravenous infusion for a cycle of 3 weeks.

Interventions

BL-B01D1

Administration by intravenous infusion for a cycle of 3 weeks.

Intervention Type: DRUG

Pembrolizumab

Administration by intravenous infusion for a cycle of 3 weeks.

Intervention Type: DRUG

Other Intervention Names

iza-bren; izalontamab brengitecan; BMS-986507

Eligibility Criteria

Inclusion Criteria

1. Sign the informed consent form voluntarily and follow the protocol requirements;

2. Gender is not limited;

3. Age ≥18 years old and ≤75 years old;

4. Expected survival time ≥3 months;

5. Patients with advanced biliary tract cancer confirmed by histology or cytology;

6. Patients must provide a documented tumor tissue specimen of the primary or metastatic tumor within 3 years for PD-L1 testing and other testing;

7. At least one measurable lesion meeting the RECIST v1.1 definition was required;

8. ECOG score 0-1;

9. The toxicity of previous antineoplastic therapy has returned to ≤ grade 1 as defined by NCI-CTCAE v5.0;

10. No severe cardiac dysfunction, left ventricular ejection fraction ≥50%;

11. Organ function level must meet the requirements;

12. Coagulation function: international normalized ratio (INR) ≤1.5×ULN, and activated partial thromboplastin time (APTT) ≤1.5×ULN;

13. Urinary protein ≤2+ or ≤1000mg/24h;

14. For premenopausal women of childbearing potential, a pregnancy test must be performed within 7 days before starting treatment, a serum or urine pregnancy test must be negative, and the patient must not be lactating; All enrolled patients should take adequate barrier contraception during the entire treatment cycle and for 6 months after the end of treatment.

Exclusion Criteria

1. Patients with active central nervous system metastases;

2. Who had participated in any other clinical trial within 4 weeks before the trial dose;

3. Received anti-tumor therapy such as chemotherapy, radiotherapy and biological therapy within 4 weeks before the first use of study drug;

4. Had undergone major surgery (investigator-defined) within 4 weeks before the first dose;

5. Had received immunotherapy and developed grade ≥3 irAE or grade ≥2 immune-related myocarditis;

6. Use of immunomodulatory drugs within 14 days before the first dose of study drug;

7. Systemic corticosteroids or immunosuppressive agents were required within 2 weeks before the study administration;

8. Pulmonary disease grade ≥3 according to NCI-CTCAE v5.0; A history of ILD/pulmonary inflammation requiring steroid treatment;

9. Severe systemic infection occurred within 4 weeks before screening;

10. Patients at risk for active autoimmune disease or with a history of autoimmune disease;

11. Other malignant tumors within 5 years before the first dose;

12. Human immunodeficiency virus antibody positive, active tuberculosis, active hepatitis B virus infection or hepatitis C virus infection;

13. Poorly controlled hypertension by two antihypertensive drugs with different mechanisms;

14. Diabetic patients with poor glycemic control;

15. Had a history of severe cardiovascular and cerebrovascular diseases;

16. Previous history of autologous or allogeneic stem cell, bone marrow or organ transplantation;

17. Subjects with clinically significant bleeding or significant bleeding tendency within the preceding 4 weeks were screened;

18. Patients with massive or symptomatic effusions or poorly controlled effusions;

19. Imaging examination showed that the tumor had invaded or wrapped around the chest, neck, pharynx and other large arteries or invaded the pericardium and heart;

20. Unstable thrombotic events requiring therapeutic intervention within 6 months before screening;

21. Prior treatment with an ADC drug with a topoisomerase I inhibitor as a toxin;

22. Patients with a history of allergy to recombinant humanized antibodies or to any of the excipients of the trial drug;

23. The cumulative dose of anthracyclines > 360 mg/m2 in previous (new) adjuvant therapy;

24. Pregnant or lactating women;

25. Who have a history of psychotropic drug abuse and cannot quit or have mental disorders;

26. The investigator did not consider it appropriate to apply other criteria for participation in the trial.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.

INDUSTRY

Sponsor Role: collaborator

Sichuan Baili Pharmaceutical Co., Ltd.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Zhongshan Hospital Fudan University

Shanghai, Shanghai Municipality, China

Site Status: RECRUITING

Countries

China

Central Contacts

Sa Xiao, PHD

Role: CONTACT

xiaosa@baili-pharm.com

15013238943

Facility Contacts

Jian Zhou

Role: primary

Other Identifiers

BL-B01D1-204-10

Identifier Type: -

Identifier Source: org_study_id